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Background: Prospective studies on maintenance treatment for Beagles with hereditary selective
cobalamin (Cbl) malabsorption (Imerslund-Gräsbeck syndrome, IGS) are lacking. In our experience,
measurement of methylmalonic acid (MMA), a Cbl-dependent metabolite, seems more helpful to
monitor Cbl status as compared with serum Cbl concentrations.
Objectives: To evaluate a standardized Cbl supplementation scheme in Beagles with IGS. We
hypothesized that a single parenteral dose of 1 mg hydroxocobalamin (OH-Cbl) would maintain
clinical and metabolic remission for up to 2 months.
Animals: Six client-owned juvenile Beagles with genetically confirmed IGS and 28 healthy control
dogs.
Methods: Prospective study. Monthly IM OH-Cbl (1 mg) supplementation was done over a median
of 9 months (range, 6-13) in 6 dogs, followed by bimonthly (every 2 months) injections in 5 dogs
over a median of 6 months (range, 3-10). Health status was assessed by routine clinical examina-
tions at injection time points and owner observations. Voided urine samples were collected
immediately before OH-Cbl injections for measurement of MMA-to-creatinine concentrations
using a gas-liquid chromatography-tandem mass spectrometry (GC-MS) method.
Results: All dogs were clinically healthy while receiving monthly and bimonthly OH-Cbl supple-
mentation. Urinary MMA results in healthy dogs ranged from 1.3 to 76.5 mmol/mol creatinine
(median, 2.9). Median urinary MMA concentrations did not differ between dogs with IGS receiving
monthly (n549; 5.3 mmol/mol creatinine; range, 2.3-50.4) and bimonthly (n531; 5.3 mmol/mol
creatinine; range, 1.6-50) injections.
Conclusions and Clinical Importance: A maintenance parenteral dose of 1 mg OH-Cbl monthly or
bimonthly appears adequate in Beagles with IGS monitored by metabolic testing.
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Gräsbeck syndrome; IF, intrinsic factor; MMA, methylmalonic acid; OH-Cbl, hydroxocobalamin; RI, reference interval
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1 | INTRODUCTION
Metabolic derivatives of cobalamin (Cbl), or vitamin B12, act as an essen-
tial cofactor of methylmalonyl-CoA mutase, which converts
methylmalonyl-CoA to succinyl-CoA. A decrease in activity of this intra-
cellular enzyme results in increases in methylmalonic acid (MMA).1 Dogs
are dependent on intestinal uptake of dietary Cbl bound to intrinsic fac-
tor (IF). The Cbl–IF complex subsequently binds to cubam, a hetero-
meric, multiligand, endocytic receptor, consisting of 2 proteins,
amnionless (AMN) and cubilin (CUBN).2 In humans, mutations in either
the AMN or CUBN genes lead to selective Cbl malabsorption known as
Imerslund-Gräsbeck syndrome (IGS).3,4 In dogs, selective intestinal Cbl
malabsorption, comparable to IGS in humans, has been described in Aus-
tralian Shepherds,5,6 Beagles,7–12 Border Collies,13–16 and Giant
Schnauzers.17 It is an autosomal recessive trait caused by 2 distinct
AMN mutations in Giant Schnauzers17 and Australian Shepherds.5 Our
group and others recently identified 2 independent CUBN mutations in
Border Collies18,19 and Beagles.10,20 Although the disease is rare, sub-
stantial carrier frequency has been noted in affected breeds20 and thus
disease occurrence is more common regionally.8 Clinical signs of IGS
usually occur in the juvenile period as fetal Cbl stores gradually diminish.
Typical clinical signs include failure to thrive, anorexia, and lethargy. Simi-
lar to infants, dogs may also be presented with more subtle clinical signs
such as intermittent pyrexia, glossitis, aphthous stomatitis, and paresthe-
sia.12,15 Laboratory abnormalities consist of neutropenia, mild to moder-
ate normocytic anemia, hyperammonemia, increased liver enzyme
activities, and mild proteinuria.8–16 Left untreated, IGS is life-threatening
as a result of metabolic derangements and immunodeficiency.9–11,16
Treatment consists of parenteral Cbl supplementation, which leads to
rapid and complete clinical remission when administered sufficiently
early in the course of disease, and the long-term prognosis is excellent
with adequate lifelong treatment.6,8–10,12 In humans with IGS, clinical
signs and biochemical variables such as MMA are monitored and usually
normalize when treatment is adequate.21–23 In dogs with IGS, long-term
monitoring (including regular assessment of markers of cellular Cbl avail-
ability) has not been carried out. Treatment regimens based on anecdotal
reports vary widely and include different doses of Cbl administered
weekly to every 4–5 months.6,7,9,10,13–15,17,24 In our experience, mea-
surement of serum Cbl concentration is not helpful for determining dos-
age frequency and response to treatment; serum Cbl concentrations
were found to be persistently subnormal even though the health status
of dogs was unremarkable and the results of periodic measurements of
MMA were normal. In terms of practicality, most owners of dogs with
IGS in our caseload eventually switched to monthly or bimonthly IM
injections of 1 mg OH-Cbl, which appeared to be effective in the long
term when assessed periodically. In Europe, genetic testing for IGS in
dogs became available commercially in 2014 (www.laboklin.de) and for
the first time allowed primary care veterinarians to diagnose the disorder
before critical illness occurred.9–11,16 Our continuing education articles
on IGS (http://www.zora.uzh.ch/id/eprint/61072/; http://www.zora.
uzh.ch/id/eprint/112847/; Lutz S, Bigler B, Sewell A, Riond B, Reusch
CE, Kook PH. Ein Vitaminmangel mit weitreichenden Folgen. Hunde
2012(2):86–89.) prompted primary care veterinarians and owners of
dogs with IGS to contact us for advice on metabolic monitoring of Cbl
status. This gave rise to the idea of monitoring urine concentrations of
MMA in dogs newly diagnosed with IGS. We hypothesized that a single
parenteral dose of 1 mg Cbl could maintain clinical and metabolic remis-
sion for up 2 months in Beagles with genetically confirmed IGS.
2 | MATERIALS AND METHODS
2.1 | Animals
The clinical and metabolic health of six client-owned purebred Beagles
with IGS was monitored for a minimum of 6 months. All six dogs had
been diagnosed with IGS in private practice using a commercial genetic
test (www.laboklin.de) for the CUBN mutation. The median age at the
time of genetic testing was 8 months (range, 2–11 months). There
were 3 female (1 spayed) and 3 male (2 neutered) dogs. The 2 youngest
dogs (1 male, 1 female; each 2 months old) were littermates. Median
body weight at the beginning of monthly Cbl supplementation was
7 kg (range, 5–13 kg). At the time of diagnosis, 4 of 6 dogs had clinical
signs of IGS, which included failure to thrive (4/4), lethargy (4/4), ano-
rexia (4/4), small stature (3/4), recurrent diarrhea (2/4), intermittent
vomiting (1/4), and episodic fever and generalized pain (1/4). The 2
youngest dogs (littermates) had no clinical signs of IGS. Serum Cbl con-
centration at the time of diagnosis was below the detection limit (74
pmol/L) of the assay (Laboklin Bad Kissingen, Germany. B12 ECLIA on
Cobas 8000 e602.) in the four older dogs and subnormal (IDEXX
GmbH Ludwigsburg, Germany. Cbl chemiluminescence assay on
ADVIA Centaur XP) in the two youngest dogs. Laboratory abnormal-
ities in the clinically affected dogs consisted of mild neutropenia (3),
mild normocytic anemia (1), and mild proteinuria (dipstick analysis). The
four dogs with clinical signs had been treated with cyanocobalamin
(CN-Cbl), administered IM, before beginning monthly supplementation.
The amount and frequency of administration of CN-Cbl in the initial
replenishment period differed considerably and was 100 mg q7d
(n52), 1500 mg q7d (n51), or 1000 mg, q4wk (n51) before the first
urine sample (t0) was collected. All six dogs were considered to be free
of clinical signs by their owners and the primary care veterinarians at
the time of the baseline urine evaluation.
2.2 | Study design
2.2.1 | Beagles with IGS
A baseline voided urine sample was collected before the first (t0) injec-
tion of 1 mg hydroxocobalamin (OH-Cbl; VITAMIN B 12 Depot Rotex-
medica Injektionsl€osung, 22946 Trittau, Germany). Thereafter, the dogs
received 1 mg OH-Cbl (VITAMIN B 12 Depot Rotexmedica Injek-
tionsl€osung, 22946 Trittau, Germany), administered IM, once monthly,
by the primary care veterinarian. History and physical examination
were carried out at each scheduled appointment for OH-Cbl adminis-
tration. After the collection of urine samples and OH-Cbl injections
were done in the same manner each time, and all urine samples were
stored at 2208C for analysis later. Our protocol called for a decrease in
the interval between OH-Cbl injections if health problems attributable
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to Cbl deficiency occurred. The definition of health problems was delib-
erately kept broad because IGS can manifest itself in a variety of clinical
signs. The injection interval was changed from once monthly to once
every 2 months (bimonthly) when the clinical well-being of the dogs
and the results of urinary MMA measurements indicated adequate Cbl
supplementation. The dosing schedule was changed to bimonthly injec-
tions after 6 monthly injections in 2 dogs and after 12 monthly injec-
tions in 3 dogs. The owner of 1 of the dogs was not willing to collect
urine samples after 6 months and thus the dosing schedule remained
monthly. Serum Cbl concentrations have been shown to be of limited
value for the assessment of Cbl status in dogs with IGS,17 and thus the
decision to include this variable along with urinary MMA concentration
was ultimately left to the discretion of the primary care veterinarian
and owner. When included, serum samples for Cbl determination were
taken immediately before OH-Cbl injections. All urine samples were
shipped on dry ice and by a commercial carrier (n53) or brought to
our clinic by the owner (n53).
2.2.2 | Healthy control dogs
Urinary MMA concentrations were determined in 28 clinically healthy
dogs that belonged to staff or students and had normal routine labora-
tory (CBC, serum biochemistry, and urinalysis) results and normal
serum Cbl concentrations. There were 5 purebred Beagles (all tested
negative for IGS), 4 Labrador Retrievers, 2 Borzois, as well as 12 other
breeds and 5 mixed-breed dogs. Immediately frozen voided urine sam-
ples were used for analysis in all dogs. Owners of the 28 control dogs
reported that all dogs remained clinically healthy after urine collection
for a minimum of 20 months (the time of manuscript preparation).
Banked surplus serum samples from 20 healthy client-owned dogs
(mixed-breed dog [10], Labrador Retriever [2], Nova Scotia Duck Toll-
ing Retriever [1], German Shorthaired Pointer [1], Sibirian Husky [1],
Entlebucher Mountain dog [1], West Highland White Terrier [1], Stand-
ard Poodle [1], Harrier [1], Rottweiler [1]), collected as part of a differ-
ent study on laboratory reference values were used to measure serum
MMA concentrations.
2.3 | Analyses
2.3.1 | Serum Cbl concentration
Serum samples for Cbl analysis were submitted to 1 of 2 commercial
veterinary laboratories (Laboklin Bad Kissingen, Germany. B12 ECLIA
on Cobas 8000 e602; IDEXX GmbH Ludwigsburg, Germany. Cbl chem-
iluminescence assay on ADVIA Centaur XP.) by the primary care veteri-
narians (n512) or samples were frozen and shipped together with
urine samples to our laboratory (n512). Both commercial veterinary
laboratories used chemiluminescence assays for Cbl determination, and
the reference intervals (RI) were 221–590 pmol/L (74 pmol/L, lower
limit of detection; Laboklin Bad Kissingen, Germany. B12 ECLIA on
Cobas 8000 e602) and 173–599 pmol/L (33 pmol/L, lower limit of
detection; IDEXX GmbH Ludwigsburg, Germany. Cbl chemilumines-
cence assay on ADVIA Centaur XP). An automated competitive binding
chemiluminescence assay (Immulite 2000, vitamin B12, Siemens
Healthcare Diagnostics Inc, Newark, DE) with intra- and inter-assay
coefficients of variation (CV) of 2.1% and 3.4%, respectively, RI of
146–721 pmol/L and lower limit of detection of 111 pmol/L25 was
used in our laboratory.
Urine and serum MMA concentrations were analyzed at the Division
of Clinical Chemistry of the University Children’s Hospital Zurich accord-
ing to accredited methods.26 In brief, samples were supplemented with an
internal standard, precipitated, and analysis was done by gas-liquid chro-
matography-tandem mass spectrometry (GC-MS) on an Ultimate 3000
XRS UHPLC system (Dionex, Thermo Scientific, Waltham, MA) with a
SCIEX5500 mass spectrometer (SCIEX, Framingham, MA) using multiple
reaction monitoring. The lower limit of quantification for this method was
25 nmol/L in serum and 651 nmol/L in urine. Results for urine MMA
were expressed as mmol MMA per mol creatinine. Creatinine concentra-
tions were determined using a kinetic Jaffe method on a DxC600 clinical
chemistry analyzer (Beckman Coulter International S.A. Nyon, Switzerland)
using commercial reagents. The interassay CVs of the analyses were 5.8%
for MMA in serum and urine and 2.7% for creatinine in urine.
2.4 | Statistical analysis
Data were tested for normal distribution using a D’Agostino and Pearson
omnibus test. For urine and serum MMA, results of healthy dogs are pre-
sented as range and median values. Differences between urinary MMA
results obtained during monthly injections were tested using the Friedman
test, and differences between monthly and bimonthly urinary MMA con-
centrations were tested using the Mann-Whitney test. Data were ana-
lyzed by use of commercial software (GraphPad PRISM for Windows).
3 | RESULTS
3.1 | Healthy control dogs
Urinary MMA concentrations were not normally distributed in healthy
control dogs and ranged from 1.3 to 76.5 mmol/mol creatinine (median,
2.9 mmol/mol creatinine). Serum MMA concentrations in healthy dogs
ranged from 539 to 1140 nmol/L (median, 730 nmol/L).
3.2 | Response to monthly Cbl supplementation
3.2.1 | Clinical signs
Dogs received monthly OH-Cbl injections for a median of 9 (range,
6–13) months. All dogs were considered free of clinical signs and
described as active and alert by owners and whereas veterinarians
receiving monthly OH-Cbl supplementation. Body weight had
increased as appropriate for growing dogs from 7 kg to a median of
9 kg (range, 8–13 kg) after 6 months of OH-Cbl supplementation. Four
dogs were considered to be athletic based on appearance and activity
level. The results of periodic hematologic evaluations undertaken by
the primary care veterinarians were normal in all dogs. The owners of
dog 5 (Figure 2, yellow squares) were not willing to collect urine sam-
ples after 6 months but continued with monthly OH-Cbl injections.
Follow-up information was available for another 23 months, and the
dog remained clinically normal.
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3.2.2 | Serum Cbl concentration
Serum Cbl concentrations were periodically evaluated in 5 of 6 dogs
with IGS. In dog 1 (Figure 2, blue circles) serum Cbl concentrations
were available for all 6 monthly supplementation time points, and
were all below the detection limit of the assay (Immulite 2000, vita-
min B12, Siemens Healthcare Diagnostics Inc, Newark, DE). For 4
dogs, 1 serum Cbl measurement each was available. Serum Cbl con-
centration was low-normal with 212 pmol/L (IDEXX GmbH Ludwigs-
burg, Germany. Cbl chemiluminescence assay on ADVIA Centaur XP)
before the 3rd injection in dog 4 (Figure 2, red squares), and subnor-
mal before the 3rd Cbl injection in dog 5 (Figure 2, yellow squares),
before the 4th Cbl injection in dog 6 (Figure 2, green diamonds),
and before the 12th Cbl injection in dog 3 (Figure 2, purple
triangles).
3.2.3 | Urinary MMA concentrations
Fifty-five urinary MMA results were available from 6 dogs with IGS
over a median of 9 (range, 6–12) months. The median baseline urinary
MMA concentration before monthly injections was 9.6 mmol/mol cre-
atinine (range, 1.8–77.3; healthy control dogs, median 2.9, range 1.3–
76.5). The 2 highest baseline urinary MMA concentrations (77.3 and
20.6 mmol/mol creatinine) were recorded in the two 2-month old lit-
termates (dogs 2 and 3) that had not yet received Cbl supplementa-
tion. Results from dog 4 (Figure 2, red squares) differed insofar as all
12 urinary MMA concentrations determined during monthly Cbl sup-
plementation were higher (median, 36.3 mmol/mol creatinine; range,
28.2–50) than the results of the other dogs with IGS, which had uri-
nary MMA of 2 to 13.5 mmol/mol creatinine. Urinary MMA concen-
trations during monthly OH-Cbl injections did not differ among time
points (P5 .74).
3.2.4 | Additional measurement of serum MMA
concentrations in dog 1
Serum MMA concentration was measured in surplus sera from the first
6 time points of Cbl supplementation in dog 1(Figure 2, blue circles).
Results ranged from 520 to 900 nmol/L (median, 670 nmol/L; RI,
539–1140 nmol/L).
3.3 | Response to bimonthly Cbl supplementation
3.3.1 | Clinical signs
Five dogs that received bimonthly Cbl injections for a median of 6
(range, 3–10) months were without clinical signs of Cbl deficiency or
other diseases.
3.3.2 | Serum Cbl concentrations
Four dogs had serum Cbl concentrations measured. In dog 1 (Figure 2,
blue circles) serum Cbl concentrations were available for all 5
bimonthly injections; only the result at the 1st time point was in the
low-normal range (162 pmol/L), the subsequent 4 Cbl concentrations
were below the detection limit of the assay (Immulite 2000, vitamin
B12, Siemens Healthcare Diagnostics Inc, Newark, DE). Subnormal
serum Cbl concentrations were measured before the 3rd bimonthly
injection in dogs 6 (Figure 2, green diamonds) and 3 (Figure 2, purple
triangles), and before the 4th bimonthly injection in dog 2 (Figure 2,
orange triangles).
3.3.3 | Urinary MMA concentrations
Thirty-one urinary MMA results were available in 5 dogs, which were
on a bimonthly Cbl supplementation schedule, over a median of 6
(range, 3–10) months. Results ranged from 1.6 to 10.5 (median, 4.9)
mmol/mol creatinine in 4 dogs, whereas higher urinary MMA concen-
trations (45.7 to 50 mmol/mol creatinine) were detected in dog 4 (Fig-
ure 1, red squares). Urinary MMA concentrations did not differ
between bimonthly and monthly Cbl supplementation (P5 .58).
3.3.4 | Additional measurement of serum MMA
concentrations in dog 4
In dog 4, additional serum samples were available at the time of the
2nd and 3rd bimonthly OH-Cbl injections, and analysis of serum MMA
concentrations detected 657 and 591 nmol/L, respectively (range in
healthy dogs, 539–1140 nmol/L).
4 | DISCUSSION
Our findings provide evidence that the schedule for administration of
parenteral OH-Cbl can be adjusted to include longer intervals
between dosing in Beagles with IGS provided that patients are regu-
larly monitored. Intervals of up to 2 months between IM injections of
1 mg OH-Cbl appear reasonable and therefore can be recommended.
All dogs with IGS were deemed clinically normal by the primary care
veterinarians and owners throughout the Cbl supplementation period.
A similar approach is used in human medicine wherein the frequency
of Cbl injections relies primarily on the health status of the patient,
and thus the interval between injections can be increased for mainte-
nance treatment in infants with various inborn errors of cellular Cbl
metabolism.4,23,27,28 Monthly IM injections of 1 mg OH-Cbl constitute
the most common maintenance regime in children with IGS.4,22,29–31
To date, 3 original studies have investigated the long-term outcome
of maintenance schedules in humans with IGS,23,28,32 and IM injec-
tions of 1 mg Cbl up to every 6 months23 provided adequate treat-
ment. In addition, a few case reports describe similar maintenance
schedules for long-term treatment that include monthly,33,34
bimonthly,35 or trimonthly injections of 1 mg OH-Cbl.36 The situation
is quite different in dogs with IGS based on the information provided
in case studies, in which dosing intervals were highly variable with
injections being done weekly,9 every 2 weeks,6,7,10,12,14,15 once
monthly,10,13,15,17 or bimonthly,13 and in 1 case every 4–5 months.24
However, regular long-term evaluation of metabolic variables for
determining the adequacy of maintenance treatment was not done in
any of these cases. Although all published data describe the use of
CN-Cbl for treatment of dogs with IGS, OH-Cbl is considered the
treatment of choice for children with IGS4,21,23,32,37 and other types
of hereditary Cbl deficiency38,39 because it is the natural form of
Cbl40 and IM injection of OH-Cbl is thought to cause less pain than
CN-Cbl.37 For these reasons, we replaced CN-Cbl with OH-Cbl
4 | Journal of Veterinary Internal Medicine KOOK ET AL.
several years ago for Cbl supplementation in dogs. However, studies
that compare the clinical benefits of CN-Cbl and OH-Cbl have not
been reported.
Determination of urinary MMA generally is considered a reliable
and non-invasive first-line diagnostic and monitoring tool in children
with disorders of Cbl metabolism.21 A survey among European meta-
bolic centers recently showed urinary MMA to be the most valuable
variable for predicting outcome in children with inborn errors of Cbl
metabolism.38 We chose to determine MMA in urine rather than in
serum or plasma because collection of voided urine samples is less
invasive and more convenient for dog owners. In addition, we were
concerned that owner compliance would suffer if consecutive blood
sampling was required, especially when all dogs were free of clinical
signs throughout the study period.
There are currently no guidelines with regard to urinary MMA cut-
off points for IGS in humans, and positive responses to Cbl supplemen-
tation have been defined only for infants with defects of the mitochon-
drial enzyme, methylmalonyl-CoA mutase.38 Very little is known about
biochemical responses to Cbl supplementation in dogs with IGS.
Although it is well known that urinary MMA concentrations at the time
of diagnosis in untreated ill dogs are usually in the thou-
sands,6,7,9,10,13,14,17,24,25 responses to Cbl supplementation using uri-
nary MMA as a marker of cellular Cbl availability have only been
documented in 2 Border collies,13,14 2 Beagles,7,9 and 1 family of Giant
Schnauzers.17,24 Normal urinary MMA concentrations were noted with
weekly9 or biweekly7 IM injection of various doses of Cbl as well as
with parenteral administration of 1 mg Cbl every 1–2 months.13
The use of urinary MMA for monitoring the biochemical response
to treatment of IGS was described in more detail in a family of Giant
Schnauzer puppies.17 A single IM injection of 1 mg CN-Cbl was found
to be sufficient for preventing relapse of clinical and laboratory abnor-
malities for 2 months despite persistently subnormal serum Cbl
concentrations. The same puppies also had urinary MMA concentra-
tions measured using GC-MS, and urine MMA ranged from 14 to 113
mmol/mol creatinine during the 2 months post-treatment. Age-
matched control dogs excreted<34 mmol/mol creatinine.17 The
affected puppies remained healthy and grew to normal size with regu-
lar monthly IM injections of 1 mg CN-Cbl, although this was not moni-
tored long term with MMA measurements.17
Variation in urinary MMA concentrations was seen after initiation
of monthly OH-Cbl supplementation in our study in agreement with
the ranges observed in Giant Schnauzers with IGS.17 For instance, all
urinary MMA results from dog 4 (Figure 2, red squares; median, 38.9
mmol/mol creatinine; range, 28.2–50.4) and 2 urinary MMA results
from dog 2 (Figure 2, orange triangles; 24.3 and 31.1 mmol/mol creati-
nine at t5 and t9, respectively) were higher than most of recorded uri-
nary MMA concentrations, which ranged from 1.6 to 13.5 mmol/mol
creatinine. Comparable variation in urinary MMA concentration were
found also in healthy control dogs (Figure 1). Differences in urine
organic acids profiles also have been reported in populations of healthy
infants, with the highest median urinary MMA (95th percentile) of 5.2
(49) mmol/mol creatinine and 29.9 (78.9) mmol/mol creatinine seen at
1 and 6 months of age.41,42 Concentrations tend to decrease with age
because of the steady increase in creatinine excretion as infants
develop, especially up to the age of 6 months.41 The effect of creati-
nine excretion on urinary MMA concentration may be similar in dogs,
but this factor has not been assessed. However, lower muscle mass
cannot serve as an explanation for higher urinary MMA results
recorded in 3 healthy control dogs (German longhaired pointer, Wei-
maraner, Borzoi) or in dog 4 (Figure 2, red squares) because they were
all muscular dogs. Variation in intestinal bacterial metabolism, especially
production of D-lactate and 3-hydroxypropionate, is another well-
known cause of discrepancies in urinary MMA excretion in
humans.21,41 An effect of prior food intake on urinary MMA seems less
FIGURE 1 Median (horizontal lines) and individual urinary MMA concentrations (mmol/mol creatinine) from urine samples of 28 healthy
control dogs, 6 dogs with IGS undergoing monthly, and 5 dogs with IGS undergoing bimonthly supplementation with 1 mg
hydroxocobalamin, administered intramuscularly
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likely because all dogs were fed commercial dog foods and postprandial
urinary MMA concentrations have been shown only to reach 3 mmol/
mol of creatinine in humans.43 Because ranges in urinary MMA concen-
tration were similar in IGS and healthy control dogs and all urine sam-
ples were spontaneously voided, the scattered urinary MMA
concentrations might have well been caused by bacterial biosynthesis
of MMA.44,45 Probably the strongest indicator for adequate metabolic
Cbl supplementation was the simultaneously low serum MMA concen-
trations in dog 4, when receiving bimonthly OH-Cbl supplementation.
Serum MMA results from dog 1 (with low urine MMA results; Figure 2,
blue circles) were equally low during the first 6 months of monthly
OH-Cbl injections, further corroborating our theory of bacterial con-
tamination of urine as a source of urinary MMA. Although we are cur-
rently in the process of establishing a more robust RI for serum MMA
in dogs, our serum MMA results (539–1140 nmol/L) established to
date in 20 healthy dogs compare favorably to what has been published
recently using similar methodology in 43 healthy dogs (414.7–1192.5
nmol/L).46
It has been our long-term experience that serum Cbl concentration
can be subnormal or low-normal in treated dogs with IGS that are clini-
cally healthy and have normal MMA or homocysteine concentrations,
and thus we did not use serum Cbl concentration as a marker for moni-
toring Cbl status. Subnormal Cbl concentrations also have been
reported in dogs with IGS that were receiving long-term Cbl
supplementation and were clinically normal.7,14,15,17 Our results
showed that only 2 of 24 random serum Cbl measurements were in
the low-normal range, and all other concentrations were subnormal
(n511) or even below the detection limit of the assay (n511). The
two normal Cbl concentrations were recorded in dog 4 (Figure 2, red
squares) immediately before the 3rd monthly Cbl injection when uri-
nary MMA was 42 mmol/mol creatinine and in dog 1 (Figure 2, blue
circles) immediately before the first bimonthly Cbl injection when uri-
nary MMA concentration was 8.8 mmol/mol creatinine. The reason for
the discrepancy between serum Cbl and urinary MMA concentrations
currently is unclear. It is unlikely that pre-analytical factors played a
role because samples were routinely processed and it was recently
shown that the effects of extended light exposure and room tempera-
ture on serum Cbl concentrations were very small.47 It is possible that
the half-life of Cbl bound intracellularly as a coenzyme is longer than
the residence time of Cbl in the circulation, which would mean that Cbl
continues to be active in tissues and Cbl-dependent metabolism
remains normal even when serum concentrations are low. This theory
seems plausible given the excellent health status of all IGS dogs, and
their MMA concentrations in the range of healthy control dogs.
Another possibility is that the lower limit of the serum Cbl RI does not
adequately reflect the cellular Cbl status of all dogs. Similar results have
been published recently in a study on associations between serum Cbl
and MMA concentrations in dogs. More than one-third of 72 dogs
FIGURE 2 Urinary MMA concentrations (mmol/mol creatinine) in 6 dogs with IGS during monthly, and in 5 dogs with IGS during
bimonthly (*) supplementation with 1 mg OH-Cbl, administered intramuscularly
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with undetectable serum Cbl concentrations had normal serum MMA
results.46 This dilemma could be solved by measuring the concentration
of circulating Cbl bound to its transport protein (holotranscobalamin)
and its saturation index.48 Holotranscobalamin is the biologically active
Cbl fraction that can be delivered to all DNA-synthesizing cells, and its
measurement appears to better reflect recent Cbl absorption in
humans.49 However, these assays currently are not available for dogs.
Our investigation had several limitations. Simultaneous measure-
ment of serum MMA along with all urinary MMA measurements would
have been useful for assessing the clinical relevance of some of the
higher urinary MMA results. In addition, urine samples collected by cys-
tocentesis as well as voiding would have helped to determine whether
bacterial contamination was a factor affecting urinary MMA concentra-
tions. However, doing so was not possible with the study design, and
because all dogs did well clinically, additional blood sampling and
repeated cystocentesis were deemed inappropriately invasive.
At the time of writing, all dogs had been monitored for more than
30 months and were doing well clinically with normal hematologic
results. In addition, 2 dogs are now on trimonthly OH-Cbl injections,
and Cbl supplementation has been changed to the PO route (1 mg
once daily; B12 Ankermann W€orwag Pharma GmbH & Co. KG, 71034
B€oblingen, Germany) in 3 dogs. We continue to monitor biochemical
variables and plan to publish the results later. We have had positive
experiences with PO supplementation in older Beagles and Border Col-
lies with IGS from our clinic caseload that did not tolerate the injections
anymore. These dogs are clinically normal and have normal hematologic
results. Similarly, successful treatment with PO Cbl (1 mg biweekly)
also has been reported in humans with IGS, but the frequency of PO
intake is still debated.50
In conclusion, a maintenance dosage of 1 mg OH-Cbl administered
IM appears adequate for maintaining normal clinical status and urinary
MMA concentrations for up to 2 months in Beagles with IGS. Our find-
ings suggest that bimonthly parenteral supplementation with OH-Cbl is
safe and efficacious for long-term treatment of Beagles with IGS
caused by a mutation in the CUBN gene. Further studies are needed to
assess if comparable results can be achieved when treating dogs of
other known breeds with IGS.
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